Pharming (PHAR) Profit After Tax (2020 - 2026)

Pharming (PHAR) has 7 years of Profit After Tax data on file, last reported at $28.0 million in Q2 2026.

• Quarterly Profit After Tax rose 397.58% year-over-year to $28.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $28.0 million (up 353.83% YoY) and the FY2025 annual result came in at $2.5 million, up 121.43% from the prior year.
• Profit After Tax grew to $28.0 million in Q2 2026, from -$14.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $28.0 million in Q2 2026 to a low of -$20.5 million in Q1 2024.
• A 5-year average of -$1.5 million and a median of -$4.1 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 5877.78% — and 2025, when it jumped 1623.38%.
• Tracing PHAR's Profit After Tax over 5 years: stood at $13.6 million in 2022, then plunged by 188.03% to -$12.0 million in 2023, then soared by 57.18% to -$5.1 million in 2024, then slumped by 130.24% to -$11.8 million in 2025, then jumped by 336.54% to $28.0 million in 2026.
• The last three Profit After Tax figures came in at $28.0 million (Q2 2026), -$14.3 million (Q1 2026), and -$11.8 million (Q4 2025), per Business Quant data.